Skip to main content

BioTech

Why CRISPR Will Be at the Forefront of AI

Published

Mar 23, 2023

About this Series

ETF Listings Featured Insights

The latest trends and insights from ETF thought leaders and subject matter experts.

Kelly ETFs Founder & CEO Kevin Kelly joins Jill Malandrino on Nasdaq TradeTalks to discuss why CRISPR will be at the forefront of AI, imaging, and sequencing on top of being commercialized. (XDNA)

No transcript available

More in this Series

See all

A Drug Being Developed to Treat Anxiety and Cognitive Decline in the Elderly

Aug 9, 2023
Making Drugs Better by Turning Injectable Drugs Into Pill Form

Aug 9, 2023
Powering Healthcare Ventures: Alpha Healthcare Acquisition Corp III

Jul 6, 2023

My Quotes
My European Quotes
Watchlist

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ETFs and more asset classes.

/

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Shares, Indexes, ETP and more asset classes.

/

Edit Watchlist

Your Watchlist is empty.

Create your Watchlist to save your favorite quotes on Nasdaq.com. Log in or create a free account to get started.

/